Skip to content

Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00211432
Enrollment
4
Registered
2005-09-21
Start date
2008-04-30
Completion date
2010-04-30
Last updated
2012-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases, Pseudovitellium Detachment

Brief summary

The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control pseudovitelliform detachment.

Interventions

Sponsors

Alcon Research
CollaboratorINDUSTRY
Manhattan Eye, Ear & Throat Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of patients with pseudovitellium detachment. 2. Patients must be at least 18 years of age. 3. Visual acuity of 20/30 to 20/320 in study eye on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart 4. Visual acuity of 20/800 or better in fellow eye on the ETDRS visual acuity chart

Exclusion criteria

1. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions. 2. Patients who have undergone intraocular surgery within the last 2 months. 3. Patient participating in any other investigational drug study. 4. Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication. 5. Inability to obtain photographs to document choroidal neovascularization (CNV) (including difficulty with venous access). 6. Patient with significant liver disease or uremia. 7. Patient with known adverse reaction to fluorescein and indocyanine green or iodine. 8. Patient has a history of any medical condition which would preclude scheduled visits or completion of study 9. Patient has had insertion of scleral buckle in the study eye 10. Patient has received radiation treatment 11. Patient is on anticoagulant therapy with the exception of aspirin 12. Patient is pregnant or nursing.

Design outcomes

Primary

MeasureTime frame
Title: Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15mg)24 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026